Barclays
OCGN icon

Barclays’s Ocugen OCGN Stock Holding History

Barclays’s Portfolio OCGN Stock Details OCGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,800
Closed -$22K – 5189
2022
Q1 		$22K Buy
+6,800
New +$23.9K ﹤0.01% 4422

Other funds holding OCGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Barclays's OCGN Position: Q2 2026 in Review

Barclays increased its Ocugen (OCGN) stake by 59% in Q2 2026, buying an estimated $207K and bringing the position to 366,579 shares worth $561K. The position accounts for ﹤0.01% of the portfolio, ranked #3146.

Barclays first reported a position in OCGN in Q2 2022 and has held it in 12 quarters since. The position peaked at $2.14M in Q3 2022. 148 funds tracked by Wall St. Rank hold OCGN as of Q2 2026.

  • Barclays held 366,579 shares of Ocugen worth $561K as of Q2 2026.
  • Barclays bought 135,961 Ocugen shares in Q2 2026, an estimated $207K.
  • Ocugen made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3146 holding.
  • Barclays first reported a position in Ocugen in Q2 2022 and has held it in 12 quarters since.
  • Barclays's Ocugen position peaked at $2.14M in Q3 2022.
  • 148 funds tracked by Wall St. Rank held Ocugen as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.